Evofem Biosciences

Evofem Biosciences, Inc.

1 Investors
Biopharmaceutical
SAN DIEGO, CA

Evofem Biosciences, Inc. is a biopharmaceutical company focused on women's sexual and reproductive health. They develop and commercialize hormone-free, patient-controlled solutions, providing women with greater control over their health choices. The company addresses unmet needs in contraception, vaginal infections, and sexually transmitted infections.

Products & Team

Phexxi

Contraceptive vaginal gelSeed

Phexxi is the first and only FDA-approved, hormone-free, on-demand contraceptive vaginal gel. Using a proprietary vaginal pH modulator, it is applied 0-60 minutes before intercourse to maintain a slightly acidic vaginal environment, which helps prevent sperm from fertilizing an egg.

Value Proposition

Offers an alternative to traditional hormonal contraceptives for women seeking more control and fewer side effects.

Pain Points

Need for hormone-free contraception, treatment for bacterial infections, and convenient contraceptive solutions

Hormone-freeEasy-to-useNon-invasiveOn-demand contraception

Saundra Pelletier

Company Signatory
Chief Executive Officerat Evofem Biosciences, Inc.
Joined Evofem Biosciences, Inc.
April 2025

Tony O'Brien

Directorat Evofem Biosciences, Inc.
Joined Evofem Biosciences, Inc.
April 2025

Saundra Pelletier

Company Signatory
Chief Executive Officerat Evofem Biosciences, Inc.
Joined Evofem Biosciences, Inc.
July 2025

Tony O'Brien

Directorat Evofem Biosciences, Inc.
Joined Evofem Biosciences, Inc.
July 2025
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
SAN DIEGO, CA
Primary headquarters

Funding History

Total Raised:
$1.7M
E

Equity, Security Offering

April 2025
$1.5M
Target
Progress
50%
Raised
$750.0K
Target
$1.5M
#000164117225004770
E

Equity, Security Offering

Closed
June 2025
$925.0K
Raised
Progress
100%
Raised
$925.0K
Target
$925.0K
#000164117225017535

Company

  • About Us

Popular Companies

  • Biophoundry
  • Ensemble Labs

© 2025 TinyTechFund. All rights reserved.